Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.
Le Saux O, Ardin M, Berthet J, Barrin S, Bourhis M, Cinier J, Lounici Y, Treilleux I, Just PA, Bataillon G, Savoye AM, Mouret-Reynier MA, Coquan E, Derbel O, Jeay L, Bouizaguen S, Labidi-Galy I, Tabone-Eglinger S, Ferrari A, Thomas E, Ménétrier-Caux C, Tartour E, Galy-Fauroux I, Stern MH, Terme M, Caux C, Dubois B, Ray-Coquard I. Le Saux O, et al. Among authors: menetrier caux c. Nat Commun. 2024 Jul 16;15(1):5932. doi: 10.1038/s41467-024-47000-5. Nat Commun. 2024. PMID: 39013886 Free PMC article. Clinical Trial.
Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study.
Mery B, Ménétrier-Caux C, Montané L, Heudel PE, Ray-Coquard I, Bachelot T, Derbel O, Augereau P, Treilleux I, Berthet J, Nkodia A, Bardin-Dit-Courageot C, Attignon V, Ferrari A, Garin G, Perol D, Caux C, Dubois B, Trédan O. Mery B, et al. Among authors: menetrier caux c. Breast Cancer (Dove Med Press). 2023 Apr 27;15:311-325. doi: 10.2147/BCTT.S400055. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 37139242 Free PMC article.
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Voissière A, Gomez-Roca C, Chabaud S, Rodriguez C, Nkodia A, Berthet J, Montane L, Bidaux AS, Treilleux I, Eberst L, Terret C, Korakis I, Garin G, Pérol D, Delord JP, Caux C, Dubois B, Ménétrier-Caux C, Bendriss-Vermare N, Cassier PA. Voissière A, et al. Among authors: menetrier caux c. Sci Transl Med. 2024 Jan 24;16(731):eadd1834. doi: 10.1126/scitranslmed.add1834. Epub 2024 Jan 24. Sci Transl Med. 2024. PMID: 38266104
Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients.
Dalle S, Verronese E, N'Kodia A, Bardin C, Rodriguez C, Andrieu T, Eberhardt A, Chemin G, Hasan U, Le-Bouar M, Caramel J, Amini-Adle M, Bendriss-Vermare N, Dubois B, Caux C, Ménétrier-Caux C. Dalle S, et al. Among authors: menetrier caux c. Oncoimmunology. 2024 Jun 26;13(1):2372118. doi: 10.1080/2162402X.2024.2372118. eCollection 2024. Oncoimmunology. 2024. PMID: 38939518 Free PMC article. Clinical Trial.
Targeting regulatory T cells.
Ménétrier-Caux C, Curiel T, Faget J, Manuel M, Caux C, Zou W. Ménétrier-Caux C, et al. Target Oncol. 2012 Mar;7(1):15-28. doi: 10.1007/s11523-012-0208-y. Epub 2012 Feb 12. Target Oncol. 2012. PMID: 22327882 Review.
MDR1-EXPRESSING CD4+ T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE.
Di Roio A, Hubert M, Besson L, Bossennec M, Rodriguez C, Grinberg-Bleyer Y, Lalle G, Moudombi L, Schneider R, Degletagne C, Treilleux I, Campbell DJ, Metzger S, Duhen T, Trédan O, Caux C, Ménétrier-Caux C. Di Roio A, et al. Among authors: menetrier caux c. J Immunother Cancer. 2023 Nov;11(11):e007733. doi: 10.1136/jitc-2023-007733. J Immunother Cancer. 2023. PMID: 37940345 Free PMC article.
MDR1 in immunity: friend or foe?
Bossennec M, Di Roio A, Caux C, Ménétrier-Caux C. Bossennec M, et al. Oncoimmunology. 2018 Sep 6;7(12):e1499388. doi: 10.1080/2162402X.2018.1499388. eCollection 2018. Oncoimmunology. 2018. PMID: 30524890 Free PMC article. Review.
66 results